Trials / Not Yet Recruiting
Not Yet RecruitingNCT06780592
Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery
The Efficacy of Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery: a Study Protocol for a Prospective, Open-label ,Multi-center, Randomized, Controlled Trial in China
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Huashan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the effects of Vebreltinib in primary glioblastoma patients receiving a combination therapy of chemotherapy (temozolomidel) and MET-TKI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vebreltinib + Temozolomide | Vebreltinib is a capsule in the form of 25 mg and 100mg, twice daily. Participants received Vebreltinib (300 mg Bid) in combination with Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction). |
| DRUG | Temozolomide | Participants received Temozolomide (150 mg/ m2) treatment, every 4 weeks for up to 6 cycles (Induction). |
Timeline
- Start date
- 2025-01-13
- Primary completion
- 2025-12-31
- Completion
- 2027-12-31
- First posted
- 2025-01-17
- Last updated
- 2025-01-22
Source: ClinicalTrials.gov record NCT06780592. Inclusion in this directory is not an endorsement.